Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 243.90B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | 795.40M |
| EPS (ttm) | 10.31 |
| PE Ratio | 29.51 |
| Forward PE | 14.66 |
| Dividend | 9.70 (3.19%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 1,159,695 |
| Average Volume | 1,430,667 |
| Open | 304.70 |
| Previous Close | 304.20 |
| Day's Range | 304.60 - 308.70 |
| 52-Week Range | 212.90 - 313.80 |
| Beta | 0.17 |
| RSI | 55.77 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche Annual General Meeting 2025
Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders...
Roche abandons global diversity targets on concern over U.S. executive orders
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based t...
Roche Holding Has A Canadian Depositary Receipt
Sarepta plunges after death linked to Elevidys
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
Basel, 17 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, fro...
Notable healthcare headlines for the week: Merck, Novo Nordisk, J&J and Roche in focus
Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead.
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
Roche agrees biggest-ever obesity drug deal
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche And Zealand Team Up To Develop Petrelintide
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche Holdings AG (OTC: RHHBY) confirmed a licensing agreement with Zealand Pharma on Wednesday that will see the two companies co-develop petrelintide . Petrelintide is Zealand Pharma's amylin analo...
New drug candidate will help people lose weight in an easier way, Zealand Pharma CEO says
Zealand Pharma CEO Adam Steensberg discusses the companys new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Basel, 12 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with ...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard's Enterprise Research Campus in Allston
Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard's Enterprise Research Campus in Allston which will furt...
Noted Family Office Leader Stephan Roche Joins BanyanGlobal Family Business Advisors Partnership Group
BOSTON--(BUSINESS WIRE)--Today, BanyanGlobal Family Business Advisors announced that Stephan Roche, former CEO of Walton Enterprises and COO of Cascade Asset Management – the private investment office...